H.C. Wainwright Reiterates Buy Rating on Monopar Therapeutics (MNPR)

June 2, 2026 6:58 AM

H.C. Wainwright analyst Andres Y. Maldonado reiterated a Buy rating and $105.00 price target on Monopar Therapeutics (NASDAQ: MNPR).The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found